Immix Biopharma, Inc. (IMMX)
NASDAQ:IMMX
Want to see IMMX full AI Analyst Report?
IMMX Stock Chart & Stats
$10.35
-$0.03(-1.32%)
At close: 4:00 PM EST
$10.35
-$0.03(-1.32%)
Day’s Range― - ―
52-Week Range$1.70 - $11.61
Previous Close$2.25
Volume74.23K
Average Volume (3M)804.18K
Market Cap
$539.13M
Enterprise Value$429.31M
Total Cash (Recent Filing)$100.41M
Total Debt (Recent Filing)$1.07M
Price to Earnings (P/E)―
Beta1.22
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.72
Shares Outstanding53,012,093
10 Day Avg. Volume678,723
30 Day Avg. Volume804,180
Financial Highlights & Ratios
PEG Ratio-0.34
Price to Book (P/B)1.84
Price to Sales (P/S)0.00
P/FCF Ratio-6.99
Enterprise Value/Market Cap0.80
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-2.87K
Enterprise Value/Ebitda-14.53
Forecast
1Y Price Target
$18.25Price Target Upside76.33% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.77
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical EfficacyHigh complete hematologic response rates combined with extensive minimal residual disease negativity suggest deeper and potentially durable remissions compared with existing therapies.
Regulatory ProgressCompletion of enrollment in the pivotal NEXICART-2 trial enables progression toward regulatory milestones and supports a potential regulatory filing based on trial momentum.
Safety ProfileReported absence of severe cytokine release syndrome and no observed neurotoxicity points to a favorable safety profile that may improve clinician and patient acceptance.
Bears Say
Competitive ThreatAdvancing bispecific antibody therapies represent a competitive threat that could erode long-term market share for CAR-T approaches in the same indication.
Financial PerformanceOperating losses and elevated research and administrative expenses increase near-term pressure on profitability and could weigh on company valuation.
Immix Biopharma News
IMMX FAQ
What was Immix Biopharma, Inc.’s price range in the past 12 months?
Immix Biopharma, Inc. lowest stock price was $1.70 and its highest was $11.61 in the past 12 months.
What is Immix Biopharma, Inc.’s market cap?
Immix Biopharma, Inc.’s market cap is $539.13M.
When is Immix Biopharma, Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Immix Biopharma, Inc.’s earnings last quarter?
Currently, no data Available
Is Immix Biopharma, Inc. overvalued?
According to Wall Street analysts Immix Biopharma, Inc.’s price is currently Undervalued.
Does Immix Biopharma, Inc. pay dividends?
Immix Biopharma, Inc. does not currently pay dividends.
What is Immix Biopharma, Inc.’s EPS estimate?
Immix Biopharma, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Immix Biopharma, Inc. have?
Immix Biopharma, Inc. has 53,012,093 shares outstanding.
What happened to Immix Biopharma, Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Immix Biopharma, Inc.?
Currently, no hedge funds are holding shares in IMMX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Immix Biopharma Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$18.25 (76.33% Upside)
$18.25 (76.33% Upside)
Blogger Sentiment
Bullish
IMMX Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 338.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 5.9%
Last 30 Days ▼ 5.9%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
531.09%
12-Months-Change
Fundamentals
Return on Equity
-101.24%
Trailing 12-Months
Asset Growth
356.86%
Trailing 12-Months
Company Description
Immix Biopharma, Inc.
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing various tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. The company was incorporated in 2012 and is headquartered in Los Angeles, California.
IMMX Stock 12 Month Forecast
Average Price Target
$18.25
▲(76.33% Upside)
Technical Analysis
Alterity Therapeutics
―
VistaGen Therapeutics
―
―
MindWalk Holdings
―
MiNK Therapeutics
―
Ownership Overview
23.06% Insiders
7.72% Mutual Funds
<0.01% Other Institutional Investors
65.73% Public Companies and
Individual Investors